Some of it is in the new Boston home of Eli Lilly & Co., a $700 million research ... Meanwhile, at the other end of Boston’s Seaport District, a new lab and amenities building developed at ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport ... of R&D at Eli Lilly before moving ...

BOSTON--(BUSINESS WIRE)--#Impact--Latus Bio ... Ms. Hewitt recently concluded a 25-year tenure at Eli Lilly that culminated as Global Head of Business Development for Lilly Catalyze. Her career spans ...

Eli Lilly applied for a tax abatement under the Texas Jobs, Energy, Technology and Innovation program, the Houston Business Journal reported. This initiative—the JETI program—gives a 10-year ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are pitted against each other, but only one can be my preferred healthcare stock. Where to invest $1,000 right now? Our analyst team just ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly is considering a 236-acre tract of McCord Development’s Generation Park for the manufacturing plant, which would have a direct economic impact worth $2.5B over 10 years, according to ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth stories—and it’s not just hype. Powered by blockbuster drugs for diabetes ...

Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic jolt that could accelerate the city’s ambitions to become a national ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index ...